Chinese antibody drug company established in February 2015 in the China Medical City in Taizhou, Jiangsu with 210 million US dollars of registered capital, a wholly owned subsidiary of the Hong Kong listed Mabpharm Limited (2181.HK). Develops and industrialises new drugs and biosimilars for cancer and autoimmune disease across monoclonal antibody, biosimilar and antibody technology platforms covering immune system disease, oncology, infection and endocrine and metabolic disease. Runs two production bases, with its 30,000 square metre G79 site holding four 3x1500 litre antibody bioreactor trains and matching purification lines, an injectable filling line of four million vials a year and a prefilled syringe line of one million units a year. Its approved products include Leiting for rheumatoid arthritis and other autoimmune disease, Aomaishu for allergic asthma and Enlituo (cetuximab beta injection), China's first proprietary anti-EGFR monoclonal antibody approved for colorectal cancer.
留下您的评分